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ABSTRACT: In this study, we report on novel photo-
activatable caged prodrugs of vemurafenib. This kinase
inhibitor was the ﬁrst approved drug for the personalized
treatment of BRAF-mutated melanoma and showed impressive
results in clinical studies. However, the occurrence of severe
side eﬀects and drug resistance illustrates the urgent need for
innovative therapeutic approaches. To conquer these
limitations, we implemented photoremovable protecting
groups into vemurafenib. In general, this caging concept
provides spatial and temporal control over the activation of
molecules triggered by ultraviolet light. Thus, higher inhibitor
concentrations in tumor tissues might be reached with less
systemic eﬀects. Our study describes the ﬁrst development of caged vemurafenib prodrugs useful as pharmacological tools. We
investigated their photochemical characteristics and photoactivation. In vitro evaluation proved the intended loss-of-function and
the light-dependent recovery of eﬃcacy in kinase and cellular assays. The reported vemurafenib photo prodrugs represent a
powerful biological tool for novel pharmacological approaches in cancer research.
Protein kinase inhibitors have been successfully establishedin cancer treatment over the past 15 years. However, the
occurrence of therapy-limiting side eﬀects as well as only
temporary eﬃcacy illustrates the urgent need for novel
therapeutic approaches.1 Innovative concepts that are able to
reduce adverse events and prolong duration of eﬃcacy by
overcoming tumor resistance would be of signiﬁcant beneﬁt.
Hence, we aimed to develop photoactivatable kinase
inhibitor prodrugs. These so-called caged compounds can be
activated by irradiation with ultraviolet (UV) light. The
implementation of photoremovable protecting groups (PPGs)
provides spatial and temporal control over the release of
molecules. Therefore, higher drug concentrations can be
reached in the area of interest, sparing other compartments.2
This approach might enable higher drug concentrations in
cancer-aﬄicted tissues, resulting in a faster, more eﬃcient
regression with fewer side eﬀects. Light might be applied on
superﬁcial tumors precautionarily after surgical removal or by
the use of optical ﬁbers. Beyond novel therapeutic applications,
our photo prodrugs could serve as experimental tools, e.g., for
kinetic or mechanistic studies. By irradiation with a short laser
impulse, the drug might be quickly released in certain tissues or
organism compartments.
The photo prodrug concept is essentially based on the
blockade of a pharmacophoric group. The PPG is therefore
attached to the drug molecule by a covalent bond. This bond
then has to be cleaved by radiant energy, releasing the parent
bioactive compound. o-Nitrobenzylic derivatives have been
widely used as PPGs in various biological applications. The ﬁrst
and most prominent example is certainly the photorelease of
caged adenosine triphosphate (ATP) by Kaplan and co-workers
in 1978.3 Since then, intensive research has been carried out
concerning various classes of protecting groups and evaluation
of their photocharacteristics.2
While the caging concept has been successfully applied on
various bioagents,4−6 there are only a few reports on
photoprotected kinase inhibitors. For instance, Morckel et al.
used a photoactivatable small-molecule Rho kinase inhibitor.7
This tool compound was used to uncover molecular
mechanisms of embryonic development in Xenopus laevis by
targeting speciﬁc regions of the living embryo.7 In addition,
small molecular equivalents of Src kinase have been caged8 as
well as peptidic PKA inhibitors.9 Furthermore, light-regulated
protein kinase C peptide-based sensors10 and tyrosine kinase
reporters11 have been described.
In our study, we focused on BRAFV600E inhibitor vemurafenib
(1, Zelboraf, Plexxikon/Roche). This serine/threonine kinase
inhibitor shows excellent UV stability at 365 nm and is readily
chemically accessible regarding the caging concept. Vemur-
afenib was the ﬁrst personalized drug for the therapy of BRAF
mutant cancer. It received approval for the treatment of
metastatic melanoma with BRAFV600 mutation in the United
States and Europe in 2011 and 2012, respectively.12
Introduction of vemurafenib into melanoma therapy showed
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impressive clinical results.13−15 However, despite outstanding
tumor regressions and distinctive improvements in survival,
vemurafenib cannot cure metastatic melanoma. Moreover, the
massive dosage of up to 960 mg daily leads to a high incidence
of severe adverse events such as arthralgia (joint pain), skin
rash, and the development of squamous cell carcinoma.14,16,17
Furthermore, most patients suﬀer from lethal relapse due to
drug resistance developed after only a few months of
therapy.18−22
Here, we report on the design, synthesis, and biological
evaluation of photoactivatable prodrugs of vemurafenib. First,
molecular modeling revealed promising pharmacophoric
groups to be protected by PPGs. After showing the UV
stability of vemurafenib at 365 nm, caged prodrugs were
synthesized. In the next step, these prodrugs were photo-
chemically characterized. This included assignment of an
optimal wavelength for deprotection and investigation of
photoinduced release of vemurafenib. Subsequently, determi-
nation of BRAFV600E Kd values and a broad kinase selectivity
proﬁle for these compounds proved the intended loss-of-
function by photoprotection. Finally, recovery of vemurafenib
eﬃcacy by UV irradiation in cells could be demonstrated within
proliferation assays as well as by western blot analysis.
With the presented vemurafenib photo prodrugs in hand, we
have created a powerful biological tool for novel pharmaco-
logical approaches in cancer research.
■ RESULTS AND DISCUSSION
Molecular Modeling. We ﬁrst examined ligand−protein
interactions of vemurafenib in the active site of BRAFV600E by
molecular modeling. In order to design eﬀectless vemurafenib
prodrugs, it was necessary to deﬁne key pharmacophoric
moieties of this kinase inhibitor to be subsequently blocked by
PPGs.
In Figure 1A,B, the binding mode of vemurafenib in the ATP
pocket of BRAFV600E is shown (PDB code 3OG7;23 for 2D
ligand interaction diagram, see Supporting Information Figure
S1). Herein, the type-I ATP-competitive inhibitor vemurafe-
nib23 is addressing key H-bonds by its 7-azaindole moiety
toward the hinge region.24 Furthermore, the sulfonamide NH
residue of vemurafenib interacts with backbone amides of
another highly conserved amino acid sequence, namely, Asp-
Phe-Gly (DFG motif). This DFG motif is located at the
beginning of the activation loop (A-loop), which controls
substrate access to the active site.25 Hence, both the 7-azaindole
and sulfonamide are considered to be suitable pharmacophoric
moieties for photoprotection. In line with this notion, modeling
PPG-vemurafenib compounds 2 and 4 in the active site of
BRAFV600E resulted in signiﬁcant sterical clashes, indicating
nonplausible binding modes (Figure 1C,D). However, we
assumed that blocking the central azaindole-NH moiety of
vemurafenib’s hinge binder would demolish any aﬃnity of the
photoprotected prodrugs to every other kinase as well since all
type I and II inhibitors use this interaction.24 On the other
hand, prodrugs with a PPG attached to the sulfonamide residue
might still show some aﬃnity to kinases featuring a ﬂexible
binding pocket in this peripheral area. In general, based on
slight molecular diﬀerences in the kinase architecture involving
shape and size of hydrophobic pockets, many tailor-made
examples of highly active and selective kinase inhibitors have
been developed.1,26
Motivated by the modeling data, we synthesized both NH-
photoprotected vemurafenib analogues and compared their
anticipated in vitro noneﬃcacy against the target enzyme
BRAFV600E and within a broad kinase panel to assess their
speciﬁcity.
UV Stability of Vemurafenib. In general, reactivation of
photoprotected prodrugs requires the parent compound’s
stability at the used wavelength of irradiated light. Otherwise,
the drug molecule would be degraded immediately after its
release or even before the bond to the PPG is cleaved. We next
examined the UV stability of vemurafenib at 365 nm. For this
purpose, we used a light-emitting diode (LED) reactor with a
wavelength of 365 nm (5.4 W; for technical information, see
Supporting Information Figures S4 and S5) to irradiate a
10 μM solution of the compound in PBS buﬀer containing 10%
DMSO. HPLC and LC-MS analysis were used for content
determination. Under these conditions, vemurafenib showed
excellent stability over a period of 20 min (see Supporting
Figure 1. Binding mode of vemurafenib and determination of
photoprotection sites. (A) The X-ray deﬁned crystal structure of
vemurafenib bound to the active site of BRAFV600E (PDB code 3OG7)
is shown. Arrows indicate the perspective of the enlarged views in (B),
(C), and (D). N- and C-lobe of the kinase are connected via the
ﬂexible hinge region. The ATP pocket is located in the cleft between
these two subdomains, occupied by vemurafenib. (B) Detailed view of
the interactions between vemurafenib and the ATP pocket. Hydrogen
bonds between the ligand and the protein backbone are indicated by
black dotted lines. The azaindole moiety addresses the hinge region by
two key H-bonds. Access to the active site is controlled by the
activation loop (A-loop), starting with the conserved amino acid
sequence Asp-Phe-Gly (DFG motif). The sulfonamide residue of the
ligand binds to this motif via two H-bonds. Superposition of
vemurafenib with azaindole caged prodrug 2 and sulfonamide caged
prodrug 4 is illustrated in (C) and (D), respectively. Red dashed lines
represent sterical clashes between the PPG (photoremovable
protecting group) and the target protein.
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Information Figures S2 and S3; for UV/vis absorption spectra
of all compounds, see Supporting Information Figure S9).
Synthesis of Caged Prodrugs. Investigation of the
binding mode revealed that both NH moieties within the
vemurafenib structure should be suitable for the caging
concept. Therefore, these functions were protected by PPGs
via nucleophilic substitution. We introduced two related o-
nitrobenzylic PPGs into the vemurafenib molecule, namely, the
4,5-dimethoxy-2-nitrobenzyl (DMNB) and 4,5-dimethoxy-2-
nitrophenylethyl (DMNPE) moieties (Figure 2).
Both azaindole (2) and sulfonamide (4) DMNB photo-
protected vemurafenib prodrugs could be synthesized (for
Figure 2. Chemical structures of vemurafenib and caged prodrugs. The chemical structures of vemurafenib (1), azaindole caged derivatives 2 and 3,
and sulfonamide caged 4 are shown.
Figure 3. Photoactivation of vemurafenib prodrugs and azaindole derivatives. Uncaging was examined for photoprotected vemurafenib derivatives
(A) and azaindole analogues (B). Ten micromolar compound solutions in PBS buﬀer containing 10% DMSO were irradiated at 365 nm (5.4 W) for
5 min and analyzed by HPLC and LC-MS. The amount of caged probe (diamonds) is plotted against released vemurafenib (triangles, A) or the
corresponding azaindole analogue (squares, B), respectively. The formation of a cyclic benzisoxazolidine intermediate could be observed (crosses)
and is discussed in Supporting Information Figure S10a. Photoactivation of the compounds in 1 mM DMSO solution is shown in Supporting
Information Figure S10b.
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details, see Supporting Information Figure S6 and Supporting
Information section 4). These two compounds enabled a
comparison to be made between the diﬀerent protection sites
concerning their photorelease characteristics and their bio-
logical evaluation, respectively. Through irradiation, the DMNB
group produces a nitroso-benzaldehyde, whereas a less toxic
ketone is released by the DMNPE moiety.2 Therefore, the
DMNPE azaindole caged vemurafenib (3) was synthesized as
well. It is noteworthy that due to sterical hindrance at the
sulfonamide only the azaindole DMNPE protected derivative
was obtained (as discussed in Supporting Information Figures
S7 and S8).
These photo prodrugs were subjected to further photo-
chemical and biological evaluation.
Photochemical Characterization of Caged Prodrugs.
In the following step, we investigated the photorelease kinetics
of 2, 3, and 4. For the prodrug concept, it is essential for the
parent compound to be released rapidly and quantitatively
upon irradiation. Wavelengths shorter than 300 nm might
damage tissues or proteins. For the photorelease experiments,
we used an LED reactor with an emission at 365 nm to irradiate
10 μM solutions of the compounds in PBS buﬀer containing
10% DMSO (for technical information, see Supporting
Information Figure S4 and S5; for the experiment in pure
DMSO, see Supporting Information Figure S10b). This
wavelength has been described for the cleavage of the inserted
PPGs, both DMNB and DMNPE.2
The results of photoinduced release of vemurafenib by our
photo prodrugs are presented in Figure 3A. Upon irradiation,
sulfonamide protected derivative 4 showed the fastest cleavage
of the PPG. After 30 s, more than 90% of vemurafenib was
released. Azaindole protected 2 and 3 were comparable to each
other in their photocharacteristics. More than 90% of
vemurafenib was released within 1 min. In the literature,
DMNPE is reported to have a higher quantum yield compared
to that of DMNB.2 However, the assumption that 3 would
show faster releasing characteristics than 2 could not be
conﬁrmed in our study. According to LC-MS and NMR
studies, the formation of a cyclic benzisoxazolidine intermediate
could be observed (for details, see Supporting Information
Figure S10a).
In order to investigate the minimal structural requirement for
the photoreaction, we investigated the vemurafenib scaﬀold in
more detail. In general, N-heterocycles are rarely described
leaving groups in photochemistry. We therefore synthesized
several azaindole analogues and characterized their photo-
chemical behavior. As illustrated in Figure 3B, caged 7-
azaindole 5 was perfectly stable against UV irradiation and did
not show any conversion. Photoprotected 3-acetyl-7-azaindole
6 could be uncaged but at a slow reaction rate. However, 3-
benzoyl-7-azaindole 7 oﬀered slightly slower photorelease
characteristics compared to those of the vemurafenib prodrugs.
This motif, therefore, can be considered to be the essential
fragment for suitable photorelease of the N-heterocycle in this
system.
In conclusion, both NH photoprotection sites within the
investigated prodrugs proved to be suitable for rapid and
quantitative photorelease. The next question addressed was
whether the protection of the NH moieties in vemurafenib
would actually diminish the eﬀect on BRAFV600E and also
suppress the antiproliferative eﬀect in cells.
Kinase Assays. We therefore determined the binding
aﬃnity of caged and uncaged compounds toward BRAFV600E in
a commercially available assay (for details, see Supporting
Information). The BRAFV600E Kd values were measured as
follows: 10 nM for vemurafenib, 440 nM for 2, 77 nM for 3,
and 79 nM for 4, respectively. In line with the modeling data,
the caged compounds exhibited a lower binding aﬃnity toward
BRAFV600E in comparison to that for vemurafenib. The lowest
binding aﬃnity was found for azaindole protected compound 2.
This is strong evidence that protection of the azaindole moiety
forestalls the inhibitor−enzyme interaction. Surprisingly,
compounds 3 and 4 still show unexpected binding toward
BRAFV600E, although their aﬃnities are signiﬁcantly less than
that of vemurafenib. The determined aﬃnities can be explained
by minute quantities of unprotected active compound in the
samples and/or instability of caged compounds resulting in the
release of vemurafenib under the assay conditions.
Subsequently, a selectivity proﬁle over 140 kinases for
vemurafenib, 2, and 4 was performed. The results are presented
in a heat map in Figure 4 (for the complete data set, see
Supporting Information Table S1). Apparently, vemurafenib at
Figure 4. Kinase selectivity proﬁling of vemurafenib and caged
prodrugs. The inhibitory eﬀect of active vemurafenib (1) and caged
derivatives 2 and 4 was tested in a panel of 140 kinases. The residual
activity of kinases was measured after incubation with 10 μM of each
compound. The data is portrayed as a heat map of the mean activity of
assay duplicates. The color code refers to the residual kinase activity
ranging from red (low residual activity) to blue (high residual activity).
Apparently, 2 inhibits signiﬁcantly less kinases than does vemurafenib
and 4.
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10 μM potently inhibits several other kinases besides
BRAFV600E. Altogether, there are 32 kinases whose activities
are reduced to less than 30% under the test conditions. The
most aﬀected kinases are BRK, MAP4K5, and DDR2. This data
clearly indicates that vemurafenib is not highly selective at the
tested concentrations in biochemical assays.
Sulfonamide caged compound 4 reduces the activity of 13
kinases to less than 30%. Its inhibitory potency against
nontarget kinases is diminished in comparison to that of
vemurafenib. However, some nonspeciﬁc interactions are still
observable. Regarding this data, it can be assumed that
protection of the sulfonamide residue prevents binding to
BRAFV600E but is still not suﬃcient enough to completely
suppress inhibition of other kinases.
In contrast, azaindole protected compound 2 inhibits only
two kinases: MAP4K5 (7% residual activity) and RIPK2 (26%
residual activity). These ﬁndings are in line with the initial
assumption that blockade of the hinge binder, the azaindole
moiety, would annihilate the aﬃnity to kinases in general more
eﬀectively than the protection of the sulfonamide residue.
Cellular Assays. On the basis of the biochemical data, we
supposed that the caged derivatives 2, 3, and 4 should show
considerably less activity in cellular assays compared to that of
vemurafenib. To prove this hypothesis, we investigated the
antiproliferative activity of the four compounds in cellular
growth assays using the melanoma cell line SKMel13, which
carries the BRAFV600E mutation.27 Dose−response curves for
the nonirradiated compounds were measured (Figure 5A).
Vemurafenib shows potent cytotoxic activity (GI50 value
0.17 μM). This ﬁnding corresponds with previous studies, that
revealed a strong inhibition of V600E-positive melanoma cells
by vemurafenib.28−30 In contrast, caged 2, 3, and 4 exhibit no
cell toxicity toward the melanoma cells in the nanomolar range
(Figure 5A). Cytostatic eﬀects occur at considerably higher
concentrations (GI50 values: 4.3 μM for 3 and 2.6 μM for 4).
Compound 2 does not show cell growth inhibition at all.
Similar results could be reproduced with other V600E-positive
melanoma cell lines: SKMel28, M14, and UACC62 (data
shown in Supporting Information Table S2). Again, the
marginal cytostatic eﬀects of the caged probes at higher
concentrations could be caused by minute impurities of
unprotected vemurafenib or by oﬀ-target eﬀects of the
compounds.
Next, we examined whether the inhibitory potency of the
photoprotected compounds in cells could be restored upon UV
irradiation. The cell growth assays described above were
performed by irradiating the cells with UV light at 365 nm
(1.8 W, 5 min) with and without compound incubation. The
dose−response curves are presented in Figure 5B. In this assay,
the UV irradiation at the applied dosage is well-tolerated by the
cells. After UV irradiation, 2, 3, and 4 show antiproliferative
activity comparable to that of unprotected vemurafenib (GI50
values: 0.19 μM for vemurafenib, 1.5 μM for 2, 0.46 μM for 3,
and 0.35 μM for 4; Figure 5B). The slightly reduced activity in
comparison to that of vemurafenib might be explained by
incomplete photorelease under the described conditions.
Summarizing the results of the proliferative cell assays, it can
be postulated that the irradiation of the caged compounds
restores the potent activity of vemurafenib.
Having demonstrated the photoactivation of vemurafenib
from its caged prodrugs, we investigated the eﬀect of the
cleaved PPG moieties on cellular growth. Caged 2, 3, and 4
were not suitable to answer this question because of the
intrinsic toxicity of the uncaged vemurafenib after irradiation.
We therefore used two model compounds: Boc protected L-
alanine (Boc-Ala) and its DMNB photoprotected derivative
(Boc-Ala-DMNB), as we considered Boc-Ala to be nontoxic
(Supporting Information Figure S11). At ﬁrst, the eﬀect of UV-
light-unexposed compounds on proliferation of the SKMel13
cells was measured. Both protected amino acid derivatives did
not show any antiproliferative eﬀects even at high concen-
trations. The same experiment was repeated implementing UV
irradiation (365 nm, 1.8 W). Irradiated Boc-Ala is still neither
cytotoxic nor cytostatic. In contrast, Boc-Ala-DMNB exhibits
distinct antiproliferative activity after irradiation at concen-
trations above 10 μM (GI50 = 34.4 μM). Therefore, it can be
assumed that the measured cell toxicity is caused by the cleaved
DMNB. However, the concentration at which the PPG shows
toxicity (10 μM) is approximately 100-fold higher than the
Figure 5. Activation of caged prodrugs in cell proliferation assays. The recovery of vemurafenib’s eﬃcacy by UV irradiation was demonstrated using
SKMel13 cells. (A) Dose−response curves of vemurafenib (1) and caged prodrugs 2, 3, and 4 were determined without UV irradiation. Cell growth
was measured 48 h after incubation with the compounds. Vemurafenib clearly shows cytotoxic eﬀects at concentrations above 1 μM. The caged
derivatives do not exhibit cytotoxic activity: the TGI mark is not reached even at high concentrations. (B) Cells were incubated for 1 h with the
compounds and then irradiated at 365 nm (1.8 W) for 5 min. Cell growth was determined 48 h after incubation with the compounds. After
irradiation, the caged derivatives show similar dose−response curves as that of active vemurafenib. GI50 = 50% growth inhibition; TGI = total growth
inhibition; LC50 = 50% lethal concentration; n = 4. Error bars represent standard deviation.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.5b00174
ACS Chem. Biol. 2015, 10, 2099−2107
2103
eﬃcacious concentration of the released vemurafenib (0.17
μM).
Western Blots. In order to investigate the impact of
vemurafenib and its caged derivatives on BRAFV600E signaling,
we performed western blot analysis, including the phosphor-
ylation of ERK as a readout downstream of BRAF. The results
for vemurafenib, 2, and 4 are shown in Figure 6 (for 3, see
Supporting Information Figure S12).
Initially, ERK phosphorylation in SKMel13 cells was
investigated after incubation with nonirradiated compounds.
Total ERK was used as a loading control. As reported for a
BRAF inhibitor,23,28−30 vemurafenib displays dose-dependent
pERK inhibition at concentrations higher than 0.01 μM. The
phosphorylation of ERK is completely blocked at concen-
trations above 0.1 μM.
According to the biochemical data, the caged compounds
reveal signiﬁcantly less inhibition of ERK phosphorylation.
Even at a concentration of 10 μM, there are detectable signals
of pERK. Consecutively, ERK phosphorylation in cells was
surveyed after incubation with compounds and subsequent UV
irradiation. No alteration in pERK inhibition by vemurafenib
could be determined with or without irradiation. This
demonstrates that the amount of phosphorylated ERK is not
dependent on UV irradiation under the described conditions.
After UV irradiation, 2, 3, and 4 exhibit the same inhibitory
potency on pERK as that of active vemurafenib. The complete
suppression of ERK phosphorylation could be demonstrated at
concentrations above 0.1 μM. Dose dependency correlates with
that of vemurafenib.
This indicates that the inhibitory eﬃcacy of vemurafenib on
BRAFV600E signaling can be completely reactivated upon
irradiation of the caged derivatives with UV light.
Both vemurafenib and its caged compounds exhibit no eﬀect
on the phosphorylation of Akt independent from UV
irradiation (see Supporting Information Figures S13 and S14).
Conclusions. In this article, we describe the design,
synthesis, and photochemical and in vitro characterization of
novel caged prodrugs of the kinase inhibitor vemurafenib.
Molecular modeling studies predicted the obviation of
inhibitory potency after insertion of a PPG into vemurafenib.
After UV stability of vemurafenib and photoactivation of the
caged inhibitors had been conﬁrmed, the compounds were
tested in diﬀerent in vitro assays.
In kinase binding assays, selectivity proﬁling, cellular assays,
and western blot analysis, we demonstrated that the insertion of
a PPG signiﬁcantly diminishes the inhibitory eﬃcacy and
promiscuity of vemurafenib. In particular, azaindole protected
compound 2 revealed hardly measurable activities even at high
concentrations, both in biochemical and cellular assays. The
nonspeciﬁc interactions toward oﬀ-target kinases could be
drastically reduced by protecting the hinge binder, the
azaindole moiety. Finally, we could clearly demonstrate that
UV irradiation (365 nm) of caged prodrugs can completely
restore the inhibitory potency of vemurafenib in proliferative
and signal transduction assays. The cellular growth assays
indicated that the applied UV dosage is well-tolerated by the
melanoma cells.
There are already some examples of caged kinase inhibitors
described in the literature.7,31 However, the herein presented
caged compounds are, to the best of our knowledge, the ﬁrst
Figure 6. Activation of inhibitory eﬀect of caged prodrugs on BRAFV600E signaling in vitro. SKMel13 cells were treated for 1 h at 37 °C with the
indicated concentrations of vemurafenib (1) and caged prodrugs 2 and 4. Subsequently, cells were lysed and immunoblotted. (A, C, E) Cells were
incubated with the corresponding compound without irradiation. (B, D, F) Cells were incubated with the corresponding compound for 1 h,
irradiated at 365 nm (1.8 W) for 5 min, and after a further 1 h of incubation, lysed and immunoblotted. The experiments were carried out in
duplicates. t-Erk = total Erk; p-Erk = phosphorylated Erk. For compound 3, see Supporting Information Figure S12. For phosphorylation of Akt, see
Supporting Information Figures S13 and S14.
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photoactivatable derivatives of an approved small-molecule
kinase inhibitor. Caged kinase inhibitors oﬀer an exciting
option for novel therapeutic applications. By targeted
irradiation, it might be possible to release high concentrations
of an active compound in a precisely controlled way in only
appropriate sites aﬄicted by disease. With this approach of
locally restricted activation, it is conceivable that systemic side
eﬀects can be prevented and the incidence of acquired
resistances, reduced. For instance, the paradoxic stimulation
of ERK phosphorylation by vemurafenib in wild-type BRAF
cells12 could presumably be reduced by a caged inhibitor.
Actually, our study is complementary to application of UV
light for medical/therapeutic purposes. For instance, the
psoralen plus UV-A (PUVA) therapy has been applied in
dermatology since the 1970s.32 The fact that UV light can be
carcinogenic is commonly known because of its DNA damaging
eﬀects, but this is only in the case of UVC and UVB radiation.
In contrast, UVA irradiation (wavelengths above 320 nm) does
not aﬀect the genetic material and is therefore not harmful at
low limited dosage.33 The implementation of light for release of
therapeutically active substances may be restricted due to low
tissue penetration. Several solutions for this problem are
possible: The required light could be transmitted to the site of
interest via optical ﬁbers or endoscopic probes. Moreover, in
selected cases, adjacent areas could be illuminated during the
surgery.
Besides the o-nitrobenzylic derivatives implemented in this
study, a variety of PPGs are described in the literature.2,6,34 By
varying the PPG, the required wavelength can be adapted. The
deepest permeation into biological tissue can be achieved by
wavelengths within the biological optical window. Wavelengths
around 800 nm should best meet this challenge.35 Hence, two-
photon excitation could be used, supposing that the caged
compound is sensitive to two-photon excitation.5
For future therapeutic applications, biological eﬀects of the
cleaved PPG and the cyclic benzisoxazolidine intermediate
should be thoroughly explored. UV irradiation of the herein
utilized o-nitrobenzylic PPGs generates supposedly toxic
nitroso compounds. In the presented cellular proliferation
assays, the released 4,5-dimethoxy-2-nitroso-benzaldehyde (the
cleaved DMNB) showed intrinsic toxicity only at concen-
trations above 10 μM. This might not be critical because the
caged compounds could be applied at much lower concen-
trations. The caged vemurafenib derivatives exhibit antiprolifer-
ative eﬀects already at concentrations around 0.1 μM.
Therefore, there might still be a wide therapeutic window for
possible applications. Due to its short half-life, the biological
eﬀect of the cyclic intermediate could not be explored in the
described assays. Further investigations in cellular assays and
animal studies could reveal the eﬀects of cleaved PPGs on
biological tissue more thoroughly.
In conclusion, we created novel caged derivatives of the
approved kinase inhibitor vemurafenib and proved that these
prodrugs can be photoactivated in vitro. Our straightforward
workﬂow implemented (1) determination of suitable pharma-
cophore moieties by modeling, (2) testing the UV stability of
the active inhibitor, (3) synthesis of caged prodrugs, (4)
characterizing their photoactivation, and (5) evaluating their
photoactivation in vitro. This rational approach can be used for
the generation of other photoactivatable (kinase) inhibitors as
well based on diﬀerent precursors and caged by various PPGs.
Additionally, caged kinase inhibitors represent a powerful
biochemical tool for studying the kinetics and regulation of
phosphorylation processes in signal transduction cascades.
These events can be precisely triggered by a short laser impulse.
On the other hand, caged kinase inhibitors create new
possibilities for therapeutic applications. Profound research
regarding the stability, bioavailability, and toxicity of the caged
kinase inhibitors is required to ensure their medical
applicability. Further cellular and animal studies are planned
to address these questions.
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